Regulation of TGF-β family signaling by inhibitory smads

Cold Spring Harbor Perspectives in Biology

Volumn 9, Issue 3, 2017, Pages

  Miyazawa, Keiji ^a   Miyazono, Kohei ^b  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; CHEMISTRY; HUMAN; METABOLISM; PROTEIN CONFORMATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; PROTEIN CONFORMATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 85014611570     PISSN: None     EISSN: 19430264     Source Type: Journal    
DOI: 10.1101/cshperspect.a022095     Document Type: Article

References (204)

1. Afrakhte M, Morén A, Jossan S, Itoh S, Sampath K, Westermark B, Heldin CH, Heldin NE, ten Dijke P. 1998. Induction of inhibitory Smad6 and Smad7 mRNA by TGFb family members. Biochem Biophys Res Commun 249: 505–511.
2. Arnold NB, Ketterer K, Kleeff J, Friess H, Buchler MW, Korc M. 2004. Thioredoxin is downstream of Smad7 in a pathway that promotes growth and suppresses cisplatin-induced apoptosis in pancreatic cancer. Cancer Res 64: 3599–3606.
3. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. 2004. Impaired Smad7-Smurf-mediated negative regulation of TGF-β signaling in scleroderma fibroblasts. J Clin Invest 113: 253–264.
4. Azuma H, Ehata S, Miyazaki H, Watabe T, Maruyama O, Imamura T, Sakamoto T, Kiyama S, Kiyama Y, Ubai T, et al. 2005. Smad7 inhibits metastasis of mouse breast cancer by direct action on cancer cells. J Natl Cancer Inst 97: 1734–1746.
5. Bachmaier K, Krawczyk C, Kozieradzki I, Kong YY, Sasaki T, Oliveira-dos-Santos A, Mariathasan S, Bouchard D, Wakeham A, Itie A, et al. 2000. Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 403: 211–216.
6. Bai S, Cao X. 2002. A nuclear antagonistic mechanism of inhibitory Smads in transforming growth factor-β signaling. J Biol Chem 277: 4176–4182.
7. Bai S, Shi X, Yang X, Cao X. 2000. Smad6 as a transcriptional corepressor. J Biol Chem 275: 8267–8270.
8. Bai Y, Yang C, Hu K, Elly C, Liu YC. 2004. Itch E3 ligasemediated regulation of TGF-β signaling by modulating Smad2 phosphorylation. Mol Cell 15: 825–831.
9. Benchabane H, Wrana JL. 2003. GATA-and Smad1-dependent enhancers in the Smad7 gene differentially interpret bone morphogenetic protein concentrations. Mol Cell Biol 23: 6646–6661.
10. Beppu H. 2013. Smad7-modified alleles by various genetargeting strategies. J Biochem 153: 399–401.
11. Berg DT, Myers LJ, Richardson MA, Sandusky G, Grinnell BW. 2005. Smad6s regulates plasminogen activator inhibitor-1 through a protein kinase C-b-dependent upregulation of transforming growth factor-β. J Biol Chem 280: 14943–14947.
12. Bitzer M, von Gersdorff G, Liang D, Dominguez-Rosales A, Beg AA, Rojkind M, Böttinger EP. 2000. A mechanism of suppression of TGF-β/SMAD signaling by NF-kB/RelA. Genes Dev 14: 187–197.
13. Boulay JL, Mild G, Lowy A, Reuter J, Lagrange M, Terracciano L, Laffer U, Herrmann R, Rochlitz C. 2003. SMAD7 is a prognostic marker in patients with colorectal cancer. Int J Cancer 104: 446–449.
14. Braunger BM, Pielmeier S, Demmer C, Landstorfer V, Kawall D, Abramov N, Leibinger M, Kleiter I, Fischer D, Jägle H, et al. 2013. TGF-β signaling protects retinal neurons from programmed cell death during the development of the mammalian eye. JNeurosci 33: 14246–14258.
15. Briones-Orta MA, Sosa-Garrocho M, Moreno-Alvarez P, Fonseca-Sánchez MA, Macías-Silva M. 2006. SnoN corepressor binds and represses smad7 gene promoter. Biochem Biophys Res Commun 341: 889–894.
16. Broderick P, Carvajal-Carmona L, Pittman AM, Webb E, Howarth K, Rowan A, Lubbe S, Spain S, Sullivan K, Fielding S, et al. 2007. A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. Nat Genet 39: 1315–1317.
17. Brodin G, Ahgren A, ten Dijke P, Heldin CH, Heuchel R. 2000. Efficient TGF-β induction of the Smad7 gene requires cooperation between AP-1, Sp1, and Smad pro-teins on the mouse Smad7 promoter. J Biol Chem 275: 29023–29030.
18. Chen Q, Chen H, Zheng D, Kuang C, Fang H, Zou B, Zhu W, Bu G, Jin T, Wang Z, et al. 2009. Smad7 is required for the development and function of the heart. J Biol Chem 284: 292–300.
19. Chen HY, Huang XR, Wang W, Li JH, Heuchel RL, Chung AC, Lan HY. 2011. The protective role of Smad7 in diabetic kidney disease: Mechanism and therapeutic potential. Diabetes 60: 590–601.
20. Choi KC, Lee YS, Lim S, Choi HK, Lee CH, Lee EK, Hong S, Kim IH, Kim SJ, Park SH. 2006. Smad6 negatively regulates interleukin 1-receptor-Toll-like receptor signaling through direct interaction with the adaptor Pellino-1. Nat Immunol 7: 1057–1065.
21. Chung AC, Huang XR, Zhou L, Heuchel R, Lai KN, Lan HY. 2009. Disruption of the Smad7 gene promotes renal fibrosis and inflammation in unilateral ureteral obstruction (UUO) in mice. Nephrol Dial Transplant 24: 1143-1154.
22. Cohen TV, Kollias HD, Liu N, Ward CW, Wagner KR. 2015. Genetic disruption of Smad7 impairs skeletal muscle growth and regeneration. J Physiol 593: 2479–2497.
23. Datta PK, Moses HL. 2000. STRAP and Smad7 synergize in the inhibition of transforming growth factor b signaling. Mol Cell Biol 20: 3157–3167.
24. Davis BN, Hilyard AC, Lagna G, Hata A. 2008. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 454: 56–61.
25. Denissova NG, Liu F. 2004. Repression of endogenous Smad7 by Ski. J Biol Chem 279: 28143–28148.
26. Denissova NG, Pouponnot C, Long J, He D, Liu F. 2000. Transforming growth factor b-inducible independent binding of SMAD to the Smad7 promoter. Proc Natl Acad Sci 97: 6397–6402.
27. Ebisawa T, Fukuchi M, Murakami G, Chiba T, Tanaka K, Imamura T, Miyazono K. 2001. Smurf1 interacts with transforming growth factor-β type I receptor through Smad7 and induces receptor degradation. J Biol Chem 276: 12477–12480.
28. Edlund S, Bu S, Schuster N, Aspenström P, Heuchel R, Heldin NE, ten Dijke P, Heldin CH, Landström M. 2003. Transforming growth factor-β1 (TGF-β)-induced apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGF-β-activated kinase 1 and mitogen-activated protein kinase kinase 3. Mol Biol Cell 14: 529–544.
29. Edlund S, Landström M, Heldin CH, Aspenström P. 2004. Smad7 is required for TGF-β-induced activation of the small GTPase Cdc42. J Cell Sci 117: 1835–1847.
30. Edlund S, Lee SY, Grimsby S, Zhang S, Aspenström P, Heldin CH, Landström M. 2005. Interaction between Smad7 and b-catenin: Importance for transforming growth factor binduced apoptosis. Mol Cell Biol 25: 1475–1488.
31. Eichhorn PJ, Rodón L, Gonzàlez-Juncà A, Dirac A, Gili M, Martínez-Sàez E, Aura C, Barba I, Peg V, Prat A, et al. 2012. USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma. Nat Med 18: 429–435.
32. El-Gohary Y, Tulachan S, Guo P, Welsh C, Wiersch J, Prasadan K, Paredes J, Shiota C, Xiao X, Wada Y, et al. 2013. Smad signaling pathways regulate pancreatic endocrine development. Dev Biol 378: 83–93.
33. El-Gohary Y, Tulachan S, Wiersch J, Guo P, Welsh C, Prasadan K, Paredes J, Shiota C, Xiao X, Wada Y, et al. 2014. A Smad signaling network regulates islet cell proliferation. Diabetes 63: 224–236.
34. Episkopou V, Arkell R, Timmons PM, Walsh JJ, Andrew RL, Swan D. 2001. Induction of the mammalian node requires Arkadia function in the extraembryonic lineages. Nature 410: 825–830.
35. Estrada KD, Retting KN, Chin AM, Lyons KM. 2011. Smad6 is essential to limit BMP signaling during cartilage development. J Bone Miner Res 26: 2498–2510.
36. Estrada KD, Wang W, Retting KN, Chien CT, Elkhoury FF, Heuchel R, Lyons KM. 2013. Smad7 regulates terminal maturation of chondrocytes in the growth plate. Dev Biol 15: 375–384.
37. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF. 2004. Cutting edge: TGF-β induces a regulatory phenotype in CD4þCD25-T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 172: 5149–5153.
38. Ferrigno O, Lallemand F, Verrecchia F, L’Hoste S, Camonis J, Atfi A, Mauviel A. 2002. Yes-associated protein (YAP65) interacts with Smad7 and potentiates its inhibitory activity against TGF-β/Smad signaling. Oncogene 21: 4879-4884.
39. Fukasawa H, Yamamoto T, Togawa A, Ohashi N, Fujigaki Y, Oda T, Uchida C, Kitagawa K, Hattori T, Suzuki S, et al. 2004. Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice. Proc Natl Acad Sci 101: 8687–8692.
40. Galvin KM, Donovan MJ, Lynch CA, Meyer RI, Paul RJ, Lorenz JN, Fairchild-Huntress V, Dixon KL, Dunmore JH, Gimbrone MA Jr, et al. 2000. A role for Smad6 in development and homeostasis of the cardiovascular system. Nat Genet 24: 171–174.
41. Glesne D, Huberman E. 2006. Smad6 is a protein kinase X phosphorylation substrate and is required for HL-60 cell differentiation. Oncogene 25: 4086–4098.
42. Goto K, Kamiya Y, Imamura T, Miyazono K, Miyazawa K. 2007. Selective inhibitory effects of Smad6 on bone morphogenetic protein type I receptors. J Biol Chem 282: 20603–20611.
43. Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery C, Karlsson S, ten Dijke P. 2003. Activin receptor-like kinase (ALK) 1 is an antagonistic mediator of lateral TGFb/ALK5 signaling. Mol Cell 12: 817–828.
44. Grönroos E, Hellman U, Heldin CH, Ericsson J. 2002. Control of Smad7 stability by competition between acetylation and ubiquitination. Mol Cell 10: 483–493.
45. Gruber T, Hinterleitner R, Hermann-Kleiter N, Meisel M, Kleiter I, Wang CM, Viola A, Pfeifhofer-Obermair C, Baier G. 2013. Cbl-b mediates TGFb sensitivity by downregulating inhibitory SMAD7 in primary T cells. J Mol Cell Biol 5: 358–368.
46. Hamzavi J, Ehnert S, Godoy P, Ciuclan L, Weng H, Mertens PR, Heuchel R, Dooley S. 2008. Disruption of the Smad7 gene enhances CCl4-dependent liver damage and fibrogenesis in mice. J Cell Mol Med 12: 2130–2144.
47. Han G, Li F, Ten Dijke P, Wang XJ. 2011. Temporal Smad7 transgene induction in mouse epidermis accelerates skin wound healing. Am J Pathol 179: 1768–1779.
48. Han G, Bian L, Li F, Cotrim A, Wang D, Lu J, Deng Y, Bird G, Sowers A, Mitchell JB, et al. 2013. Preventive and therapeutic effects of Smad7 on radiation-induced oral mucositis. Nat Med 19: 421–428.
49. Hanyu A, Ishidou Y, Ebisawa T, Shimanuki T, Imamura T, Miyazono K. 2001. The N domain of Smad7 is essential for specific inhibition of transforming growth factor-β signaling. J Cell Biol 155: 1017–1027.
50. Hata A, Lo RS, Wotton D, Lagna G, Massagué J. 1997. Mutations increasing autoinhibition inactivate tumour suppressors Smad2 and Smad4. Nature 388: 87–93.
51. Hata A, Lagna G, Massagué J, Hemmati-Brivanlou A. 1998. Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. Genes Dev 12: 186–197.
52. Hata A, Seoane J, Lagna G, Montalvo E, Hemmati-Brivanlou A, Massagué J. 2000. OAZ uses distinct DNA-and protein-binding zinc fingers in separate BMP-Smad and Olf signaling pathways. Cell 100: 229–240.
53. Ha Thi HT, Kim HY, Choi SW, Kang JM, Kim SJ, Hong S. 2015. Smad7 modulates epidermal growth factor receptor turnover through sequestration of c-Cbl.Mol Cell Biol 35: 2841–2850.
54. Hayashi H, Abdollah S, Qiu Y, Cai J, Xu YY, Grinnell BW, Richardson MA, Topper JN, Gimbrone MA Jr, Wrana JL, et al. 1997. The MAD-related protein Smad7 associates with the TGFb receptor and functions as an antagonist of TGFb signaling. Cell 89: 1165–1173.
55. He W, Li AG, Wang D, Han S, Zheng B, Goumans MJ, Ten Dijke P, Wang XJ. 2002. Overexpression of Smad7 results in severe pathological alterations in multiple epithelial tissues. EMBO J 21: 2580–2590.
56. Hong S, Lim S, Li AG, Lee C, Lee YS, Lee EK, Park SH, Wang XJ, Kim SJ. 2007. Smad7 binds to the adaptors TAB2 and TAB3 to block recruitment of the kinase TAK1 to the adaptor TRAF2. Nat Immunol 8: 504–513.
57. Hong S, Kim HY, Kim J, Ha HT, Kim YM, Bae E, Kim TH, Lee KC, Kim SJ. 2013. Smad7 protein induces interferon regulatory factor 1-dependent transcriptional activation of caspase 8 to restore tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis. J Biol Chem 288: 3560–3570.
58. Horiki M, Imamura T, Okamoto M, Hayashi M, Murai J, Myoui A, Ochi T, Miyazono K, Yoshikawa H, Tsumaki N. 2004. Smad6/Smurf1 overexpression in cartilage delays chondrocyte hypertrophy and causes dwarfism with osteopenia. J Cell Biol 165: 433–445.
59. Hua X, Miller ZA, Benchabane H, Wrana JL, Lodish HF. 2000. Synergism between transcription factors TFE3 and Smad3 in transforming growth factor-β-induced transcription of the Smad7 gene. J Biol Chem 275: 33205–33208.
60. Huang M, Sharma S, Zhu LX, Keane MP, Luo J, Zhang L, Burdick MD, Lin YQ, Dohadwala M, Gardner B, et al. 2002. IL-7 inhibits fibroblast TGF-β production and signaling in pulmonary fibrosis. J Clin Invest 109: 931–937.
61. Ibarrola N, Kratchmarova I, Nakajima D, Schiemann WP, Moustakas A, Pandey A, Mann M. 2004. Cloning of a novel signaling molecule, AMSH-2, that potentiates transforming growth factor b signaling. BMC Cell Biol 5: 2.
62. Ichijo T, Voutetakis A, Cotrim AP, Bhattachryya N, Fujii M, Chrousos GP, Kino T. 2005. The Smad6-histone deacetylase 3 complex silences the transcriptional activity of the glucocorticoid receptor: Potential clinical implications. J Biol Chem 280: 42067–42077.
63. Imamura T, Takase M, Nishihara A, Oeda E, Hanai J, Kawabata M, Miyazono K. 1997. Smad6 inhibits signalling by the TGF-β superfamily. Nature 389: 622–626.
64. Inamitsu M, Itoh S, Hellman U, ten Dijke P, Kato M. 2006. Methylation of Smad6 by protein arginine N-methyltransferase 1. FEBS Lett 580: 6603–6611.
65. Inoue H, Imamura T, Ishidou Y, Takase M, Udagawa Y, Oka Y, Tsuneizumi K, Tabata T, Miyazono K, Kawabata M. 1998. Interplay of signal mediators of decapentaplegic (Dpp): Molecular characterization of mothers against dpp, Medea, and daughters against dpp. Mol Biol Cell 9: 2145–2156.
66. Ishida W, Hamamoto T, Kusanagi K, Yagi K, Kawabata M, Takehara K, Sampath TK, Kato M, Miyazono K. 2000. Smad6 is a Smad1/5-induced Smad inhibitor. Characterization of bone morphogenetic protein-responsive element in the mouse Smad6 promoter. J Biol Chem 275: 6075–6079.
67. Itoh S, Landström M, Hermansson A, Itoh F, Heldin CH, Heldin NE, ten Dijke P. 1998. Transforming growth factor b1 induces nuclear export of inhibitory Smad7. J Biol Chem 273: 29195–29201.
68. Itoh F, Asao H, Sugamura K, Heldin CH, ten Dijke P, Itoh S. 2001. Promoting bone morphogenetic protein signaling through negative regulation of inhibitory Smads. EMBO J 20: 4132–4142.
69. Jenkins BJ, Grail D, Nheu T, Najdovska M, Wang B, Waring P, Inglese M, McLoughlin RM, Jones SA, Topley N, et al. 2005. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-β signaling. Nat Med 11: 845–852.
70. Johnsen SA, Subramaniam M, Janknecht R, Spelsberg TC. 2002a. TGFb inducible early gene enhances TGFb/ Smad-dependent transcriptional responses. Oncogene 21: 5783–5790.
71. Johnsen SA, Subramaniam M, Monroe DG, Janknecht R, Spelsberg TC. 2002b. Modulation of transforming growth factor b (TGFb)/Smad transcriptional responses through targeted degradation of TGFb-inducible early gene-1 by human seven in absentia homologue. J Biol Chem 277: 30754–30759.
72. Jung SM, Lee JH, Park J, Oh YS, Lee SK, Park JS, Lee YS, Kim JH, Lee JY, Bae YS, et al. 2013. Smad6 inhibits non-canonical TGF-β1 signalling by recruiting the deubiquitinase A20 to TRAF6. Nat Commun 4: 2562.
73. Kamiya Y, Miyazono K, Miyazawa K. 2010. Smad7 inhibits transforming growth factor-β family type I receptors through two distinct modes of interaction. J Biol Chem 285: 30804–30813.
74. Kanamaru C, Yasuda H, Takeda M, Ueda N, Suzuki J, Tsuchida T, Mashima H, Ohnishi H, Fujita T. 2001. Smad7 is induced by norepinephrine and protects rat hepatocytes from activin A-induced growth inhibition. J Biol Chem 276: 45636–45641.
75. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH, Wrana JL. 2000. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGFb receptor for degradation. Mol Cell 6: 1365–1375.
76. Kim BC, Lee HJ, Park SH, Lee SR, Karpova TS, McNally JG, Felici A, Lee DK, Kim SJ. 2004a. Jab1/CSN5, a component of the COP9 signalosome, regulates transforming growth factor b signaling by binding to Smad7 and promoting its degradation. Mol Cell Biol 24: 2251–2262.
77. Kim YH, Lee HS, Lee HJ, Hur K, Kim WH, Bang YJ, Kim SJ, Lee KU, Choe KJ, Yang HK. 2004b. Prognostic significance of the expression of Smad4 and Smad7 in human gastric carcinomas. Ann Oncol 15: 574–580.
78. Kim YC, Kim KK, Shevach EM. 2010. Simvastatin induces Foxp3þ Tregulatory cells by modulation of transforming growth factor-β signal transduction. Immunology 130: 484–493.
79. Kim TA, Kang JM, Hyun JS, Lee B, Kim SJ, Yang ES, Hong S, Lee HJ, Fujii M, Niederhuber JE, et al. 2014. The Smad7-Skp2 complex orchestrates Myc stability, impacting on the cytostatic effect of TGF-β. J Cell Sci 127: 411–421.
80. Kleeff J, Ishiwata T, Maruyama H, Friess H, Truong P, Buchler MW, Falb D, Korc M. 1999a. The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene 18: 5363–5372.
81. Kleeff J, Maruyama H, Friess H, Buchler MW, Falb D, Korc M. 1999b. Smad6 suppresses TGF-β-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer. Biochem Biophys Res Commun 255: 268–273.
82. Kleiter I, Song J, Lukas D, Hasan M, Neumann B, Croxford AL, Pedré X, Hövelmeyer N, Yogev N, Mildner A, et al. 2010. Smad7 in T cells drives T helper 1 responses in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain 133: 1067–1081.
83. Koinuma D, Shinozaki M, Komuro A, Goto K, Saitoh M, Hanyu A, Ebina M, Nukiwa T, Miyazawa K, Imamura T, et al. 2003. Arkadia amplifies TGF-β superfamily signalling through degradation of Smad7. EMBO J 22: 6458-6470.
84. Koinuma D, Shinozaki M, Nagano Y, Ikushima H, Horiguchi K, Goto K, Chano T, Saitoh M, Imamura T, Miyazono K, et al. 2011. RB1CC1 protein positively regulates transforming growth factor-β signaling through the modulation of Arkadia E3 ubiquitin ligase activity. J Biol Chem 286: 32502–32512.
85. Kollias HD, Perry RL, Miyake T, Aziz A, McDermott JC. 2006. Smad7 promotes and enhances skeletal muscle differentiation. Mol Cell Biol 26: 6248–6260.
86. Komuro A, Imamura T, Saitoh M, Yoshida Y, Yamori T, Miyazono K, Miyazawa K. 2004. Negative regulation of transforming growth factor-β (TGF-β) signaling by WW domain-containing protein 1 (WWP1). Oncogene 23: 6914–6923.
87. Kowanetz M, Lönn P, Vanlandewijck M, Kowanetz K, Heldin CH, Moustakas A. 2008. TGFb induces SIK to negatively regulate type I receptor kinase signaling. J Cell Biol 182: 655–662.
88. Krampert M, Chirasani SR, Wachs FP, Aigner R, Bogdahn U, Yingling JM, Heldin CH, Aigner L, Heuchel R. 2010. Smad7 regulates the adult neural stem/progenitor cell pool in a transforming growth factor b-and bone morphogenetic protein-independent manner. Mol Cell Biol 30: 3685–3694.
89. Krikos A, Laherty CD, Dixit VM. 1992. Transcriptional activation of the tumor necrosis factor a-inducible zinc finger protein, A20, is mediated by kB elements. J Biol Chem 267: 17971–17976.
90. Krishnan P, King MW, Neff AW, Sandusky GE, Bierman KL, Grinnell B, Smith RC. 2001. Human truncated Smad 6 (Smad 6s) inhibits the BMP pathway in Xenopus laevis. Dev Growth Differ 43: 115–132.
91. Kruithof BP, Duim SN, Moerkamp AT, Goumans MJ. 2012. TGFb and BMP signaling in cardiac cushion formation: Lessons from mice and chicken. Differentiation 84: 89–102.
92. Ku M, Howard S, Ni W, Lagna G, Hata A. 2006. OAZ regulates bone morphogenetic protein signaling through Smad6 activation. J Biol Chem 281: 5277–5287.
93. Kuang C, Xiao Y, Liu X, Stringfield TM, Zhang S, Wang Z, Chen Y. 2006. In vivo disruption of TGF-β signaling by Smad7 leads to premalignant ductal lesions in the pancreas. Proc Natl Acad Sci 103: 1858–1863.
94. Kume S, Haneda M, Kanasaki K, Sugimoto T, Araki S, Isshiki K, Isono M, Uzu T, Guarente L, Kashiwagi A, et al. 2007. SIRT1 inhibits transforming growth factor b-induced apoptosis in glomerular mesangial cells via Smad7 deacetylation. J Biol Chem 282: 151–158.
95. Kuratomi G, Komuro A, Goto K, Shinozaki M, Miyazawa K, Miyazono K, Imamura T. 2005. NEDD4–2 (neural precursor cell expressed, developmentally down-regulated 4–2) negatively regulates TGF-β (transforming growth factor-β) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF-β type I receptor. Biochem J 386: 461–470.
96. Lallemand F, Mazars A, Prunier C, Bertrand F, Kornprost M, Gallea S, Roman-Roman S, Cherqui G, Atfi A. 2001. Smad7 inhibits the survival nuclear factor kB and potentiates apoptosis in epithelial cells. Oncogene 20: 879–884.
97. Lallemand F, Seo SR, Ferrand N, Pessah M, L’hoste S, Rawadi G, Romain-Romain S, Camonis J, Atfi A. 2005. AIP4 restricts TGF-β signaling through an ubiquitination-independent mechanism. J Biol Chem 280: 27645–27653.
98. Landström M, Heldin NE, Bu S, Hermansson A, Itoh S, ten Dijke P, Heldin CH. 2000. Smad7 mediates apoptosis induced by transforming growth factor b in prostatic carcinoma cells. Curr Biol 10: 535–538.
99. Lee SJ. 2004. Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol 20: 61–86.
100. Lee YS, Park JS, Kim JH, Jung SM, Lee JY, Kim SJ, Park SH. 2011. Smad6-specific recruitment of Smurf E3 ligases mediates TGF-β1-induced degradation of MyD88 in TLR4 signalling. Nat Commun 2: 460.
101. Lee YS, Park JS, Jung SM, Kim SD, Kim JH, Lee JY, Jung KC, Mamura M, Lee S, Kim SJ, et al. 2015. Inhibition of lethal inflammatory responses through the targeting of membrane-associated Toll-like receptor 4 signaling complexes with a Smad6-derived peptide. EMBO Mol Med 7: 577–592.
102. Le Scolan E, Zhu Q, Wang L, Bandyopadhyay A, Javelaud D, Mauviel A, Sun L, Luo K. 2008. Transforming growth factor-β suppresses the ability of Ski to inhibit tumor metastasis by inducing its degradation. Cancer Res 68: 3277–3285.
103. Levy L, Howell M, Das D, Harkin S, Episkopou V, Hill CS. 2007. Arkadia activates Smad3/Smad4-dependent transcription by triggering signal-induced SnoN degradation. Mol Cell Biol 27: 6068–6083.
104. Li H, Seth A. 2004. An RNF11: Smurf2 complex mediates ubiquitination of the AMSH protein. Oncogene 23: 1801–1808.
105. Li R, Rosendahl A, Brodin G, Cheng AM, Ahgren A, Sundquist C, Kulkarni S, Pawson T, Heldin CH, Heuchel RL. 2006. Deletion of exon I of SMAD7 in mice results in altered B cell responses. J Immunol 176: 6777–6784.
106. Li Q, Zhang D, Wang Y, Sun P, Hou X, Larner J, Xiong W, Mi J. 2013. MiR-21/Smad 7 signaling determines TGF-β1-induced CAF formation. Sci Rep 10: 1038.
107. Lin X, Liang M, Feng XH. 2000. Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-β signaling. J Biol Chem 275: 36818–36822.
108. Lin X, Liang YY, Sun B, Liang M, Shi Y, Brunicardi FC, Shi Y, Feng XH. 2003. Smad6 recruits transcription corepressor CtBP to repress bone morphogenetic protein-induced transcription. Mol Cell Biol 23: 9081–9093.
109. Liu X, Lee J, Cooley M, Bhogte E, Hartley S, Glick A. 2003. Smad7 but not Smad6 cooperates with oncogenic ras to cause malignant conversion in a mouse model for squamous cell carcinoma. Cancer Res 63: 7760–7768.
110. Liu W, Rui H, Wang J, Lin S, He Y, Chen M, Li Q, Ye Z, Zhang S, Chan SC, et al. 2006. Axin is a scaffold protein in TGFb signaling that promotes degradation of Smad7 by Arkadia. EMBO J 25: 1646–1658.
111. Liu G, Friggeri A, Yang Y, Milosevic J, Ding Q, Thannickal VJ, Kaminski N, Abraham E. 2010. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 207: 1589–1597.
112. Liu GX, Li YQ, Huang XR, Wei L, Chen HY, Shi YJ, Heuchel RL, Lan HY. 2013. Disruption of Smad7 promotes ANG II-mediated renal inflammation and fibrosis via Sp1-TGF-β/Smad3-NFkB-dependent mechanisms in mice. PLoS ONE 8: e53573.
113. Lönn P, Vanlandewijck M, Raja E, Kowanetz M, Watanabe Y, Kowanetz K, Vasilaki E, Heldin CH, Moustakas A. 2012. Transcriptional induction of salt-inducible kinase 1 by transforming growth factor b leads to negative regulation of type I receptor signaling in cooperation with the Smurf2 ubiquitin ligase. J Biol Chem 287: 12867–12878.
114. Maeda S, Hayashi M, Komiya S, Imamura T, Miyazono K. 2004. Endogenous TGF-β signaling suppresses maturation of osteoblastic mesenchymal cells. EMBO J 23: 552–563.
115. Mazars A, Lallemand F, Prunier C, Marais J, Ferrand N, Pessah M, Cherqui G, Atfi A. 2001. Evidence for a role of the JNK cascade in Smad7-mediated apoptosis. J Biol Chem 276: 36797–36803.
116. Meno C, Gritsman K, Ohishi S, Ohfuji Y, Heckscher E, Mochida K, Shimono A, Kondoh H, Talbot WS, Robertson EJ, et al. 1999.Mouse Lefty2 and zebrafish antivin are feedback inhibitors of nodal signaling during vertebrate gastrulation. Mol Cell 4: 287–298.
117. Minina E, Wenzel HM, Kreschel C, Karp S, Gaffield W, McMahon AP, Vortkamp A. 2001. BMP and Ihh/PTHrP signaling interact to coordinate chondrocyte proliferation and differentiation. Development 128: 4523–4534.
118. Miyake T, Alli NS, McDermott JC. 2010.Nuclear function of Smad7 promotesmyogenesis. Mol Cell Biol 30: 722–735.
119. Miyazono K. 2000. Positive and negative regulation of TGFb signaling. J Cell Sci 113: 1101–1109.
120. Miyazono K. 2008. Regulation of TGF-β family signaling by inhibitory Smads. In The TGF-β family (ed. Derynck R, Miyazono K), pp. 363–387. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
121. Mochizuki T, Miyazaki H, Hara T, Furuya T, Imamura T, Watabe T, Miyazono K. 2004. Roles for the MH2 domain of Smad7 in the specific inhibition of transforming growth factor-β superfamily signaling. J Biol Chem 279: 31568–31574.
122. Monteleone G, Kumberova A, Croft NM, McKenzie C, Steer HW, MacDonald TT. 2001. Blocking Smad7 restores TGF-β1 signaling in chronic inflammatory bowel disease. J Clin Invest 108: 601–609.
123. Monteleone G, Mann J, Monteleone I, Vavassori P, Bremner R, Fantini M, Del Vecchio Blanco G, Tersigni R, Alessandroni L, Mann D, et al. 2004a. A failure of transforming growth factor-β1 negative regulation maintains sustained NF-kB activation in gut inflammation. J Biol Chem 279: 3925–3932.
124. Monteleone G, Pallone F, MacDonald TT. 2004b. Smad7 in TGF-β-mediated negative regulation of gut inflammation. Trends Immunol 25: 513–517.
125. Monteleone G, Del Vecchio Blanco G, Palmieri G, Vavassori P, Monteleone I, Colantoni A, Battista S, Spagnoli LG, Romano M, Borrelli M, et al. 2004c. Induction and regulation of Smad7 in the gastric mucosa of patients with Helicobacter pylori infection. Gastroenterology 126: 674–682.
126. Monteleone G, Neurath MF, Ardizzone S, Di Sabatino A, Fantini MC, Castiglione F, Scribano ML, Armuzzi A, Caprioli F, Sturniolo GC, et al. 2015. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn’s disease. N Engl J Med 372: 1104–1113.
127. Murakami G, Watabe T, Takaoka K, Miyazono K, Imamura T. 2003. Cooperative inhibition of bone morphogenetic protein signaling by Smurf1 and inhibitory Smads. Mol Biol Cell 14: 2809–2817.
128. Nagano Y, Mavrakis KJ, Lee KL, Fujii T, Koinuma D, Sase H, Yuki K, Isogaya K, Saitoh M, Imamura T, et al. 2007. Arkadia induces degradation of SnoN and c-Ski to enhance transforming growth factor-β signaling. J Biol Chem 282: 20492–20501.
129. Nagarajan RP, Zhang J, Li W, Chen Y. 1999. Regulation of Smad7 promoter by direct association with Smad3 and Smad4. J Biol Chem 274: 33412–33418.
130. Nakao A, Afrakhte M, Morén A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH, et al. 1997. Identification of Smad7, a TGFb-inducible antagonist of TGF-β signalling. Nature 389: 631–635.
131. Nakao A, Fujii M, Matsumura R, Kumano K, Saito Y, Miyazono K, Iwamoto I. 1999. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest 104: 5–11.
132. Nakao A, Miike S, Hatano M, Okumura K, Tokuhisa T, Ra C, Iwamoto I. 2000. Blockade of transforming growth factor b/Smad signaling in T cells by overexpression of Smad7 enhances antigen-induced airway inflammation and airway reactivity. J Exp Med 192: 151–158.
133. Nakayama T, Gardner H, Berg LK, Christian JL. 1998a. Smad6 functions as an intracellular antagonist of some TGF-β family members during Xenopus embryogenesis. Genes Cells 3: 387–394.
134. Nakayama T, Snyder MA, Grewal SS, Tsuneizumi K, Tabata T, Christian JL. 1998b. Xenopus Smad8 acts downstream of BMP-4 to modulate its activity during vertebrate embryonic patterning. Development 125: 857–867.
135. Nakayama T, Berg LK, Christian JL. 2001. Dissection of inhibitory Smad proteins: Both N-and C-terminal domains are necessary for full activities of Xenopus Smad6 and Smad7. Mech Dev 100: 251–262.
136. Niederlander C, Walsh JJ, Episkopou V, Jones CM. 2001. Arkadia enhances nodal-related signalling to induce mesendoderm. Nature 410: 830–834.
137. Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, Matsumoto K. 1999. The kinase TAK1 can activate the NIK-IkB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 398: 252–256.
138. Ogunjimi AA, Briant DJ, Pece-Barbara N, Le Roy C, Di Guglielmo GM, Kavsak P, Rasmussen RK, Seet BT, Sicheri F, Wrana JL. 2005. Regulation of Smurf2 ubiquitin ligase activity by anchoring the E2 to the HECT domain. Mol Cell 19: 297–308.
139. Onichtchouk D, Chen YG, Dosch R, Gawantka V, Delius H, Massagué J, Niehrs C. 1999. Silencing of TGF-β signalling by the pseudoreceptor BAMBI. Nature 401: 480–485.
140. Padgett RW, Patterson GI. 2006. C. elegans TGF-β signaling pathways. In Smad signal transduction (ed. ten Dijke P, Heldin CH), pp. 37–53. Springer, Amsterdam, The Netherlands.
141. Parikh A, Lee C, Peronne J, Marchini S, Baccarini A, Kolev V, Romualdi C, Fruscio R, Shah H, Wang F, et al. 2014. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat Commun 5: 2977.
142. Park YN, Chae KJ, Oh BK, Choi J, Choi KS, Park C. 2004. Expression of Smad7 in hepatocellular carcinoma and dysplastic nodules: Resistance mechanism to transforming growth factor-β. Hepatogastroenterology 51: 396–400.
143. Patil S, Wildey GM, Brown TL, Choy L, Derynck R, Howe PH. 2000. Smad7 is induced by CD40 and protects WEHI 231 B-lymphocytes from transforming growth factor-βinduced growth inhibition and apoptosis. J Biol Chem 275: 38363–38370.
144. Pittman AM, Naranjo S, Webb E, Broderick P, Lips EH, van Wezel T, Morreau H, Sullivan K, Fielding S, Twiss P, et al. 2009. The colorectal cancer risk at 18q21 is caused by a novel variant altering SMAD7 expression. Genome Res 19: 987–993.
145. Pulaski L, Landström M, Heldin CH, Souchelnytskyi S. 2001. Phosphorylation of Smad7 at Ser-249 does not interfere with its inhibitory role in transforming growth factor-β-dependent signaling but affects Smad7-dependent transcriptional activation. J Biol Chem 276: 14344–14349.
146. Quan T, He T, Voorhees JJ, Fisher GJ. 2005. Ultraviolet irradiation induces Smad7 via induction of transcription factor AP-1 in human skin fibroblasts. J Biol Chem 280: 8079–8085.
147. Saika S, Ikeda K, Yamanaka O, Miyamoto T, Ohnishi Y, Sato M, Muragaki Y, Ooshima A, Nakajima Y, Kao WW, et al. 2005. Expression of Smad7 in mouse eyes accelerates healing of corneal tissue after exposure to alkali. Am J Pathol 166: 1405–1418.
148. Sandusky G, Berg DT, Richardson MA, Myers L, Grinnell BW. 2002. Modulation of thrombomodulin-dependent activation of human protein C through differential expression of endothelial Smads. J Biol Chem 277: 49815–49819.
149. Schiffer M, Bitzer M, Roberts IS, Kopp JB, ten Dijke P, Mundel P, Böttinger EP. 2001. Apoptosis in podocytes induced by TGF-β and Smad7. J Clin Invest 108: 807–816.
150. Seo SR, Lallemand F, Ferrand N, Pessah M, L’Hoste S, Camonis J, Atfi A. 2004. The novel E3 ubiquitin ligase Tiul1 associates with TGIF to target Smad2 for degradation. EMBO J 23: 3780–3792.
151. Seong HA, Jung H, Ha H. 2010. Murine protein serine/ threonine kinase 38 stimulates TGF-β signaling in a kinase-dependent manner via direct phosphorylation of Smad proteins. J Biol Chem 285: 30959–30970.
152. Shen R, Chen M, Wang YJ, Kaneki H, Xing L, O’Keefe RJ, Chen D. 2006. Smad6 interacts with Runx2 and mediates Smad ubiquitin regulatory factor 1-induced Runx2 degradation. J Biol Chem 281: 3569–3576.
153. Shi Y, Massagué J. 2003. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113: 685–700.
154. Shi W, Sun C, He B, Xiong W, Shi X, Yao D, Cao X. 2004. GADD34-PP1c recruited by Smad7 dephosphorylates TGFb type I receptor. J Cell Biol 164: 291–300.
155. Shim JH, Xiao C, Paschal AE, Bailey ST, Rao P, Hayden MS, Lee KY, Bussey C, Steckel M, Tanaka N, et al. 2005. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev 19: 2668–2681.
156. Simonsson M, Heldin CH, Ericsson J, Grönroos E. 2005. The balance between acetylation and deacetylation controls Smad7 stability. J Biol Chem 280: 21797–21803.
157. Slattery ML, Herrick J, Curtin K, Samowitz W, Wolff RK, Caan BJ, Duggan D, Potter JD, Peters U. 2010. Increased risk of colon cancer associated with a genetic polymorphism of SMAD7. Cancer Res 70: 1479–1485.
158. Smith AL, Iwanaga R, Drasin DJ, Micalizzi DS, Vartuli RL, Tan AC, Ford HL. 2012. The miR-106b-25 cluster targets Smad7, activates TGF-β signaling, and induces EMTand tumor initiating cell characteristics downstream of Six1 in human breast cancer. Oncogene 31: 5162–5171.
159. Sorrentino A, Thakur N, Grimsby S, Marcusson A, von Bulow V, Schuster N, Zhang S, Heldin CH, Landström M. 2008. The type I TGF-β receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nat Cell Biol 10: 1199–1207.
160. Souchelnytskyi S, Nakayama T, Nakao A, Morén A, Heldin CH, Christian JL, ten Dijke P. 1998. Physical and functional interaction of murine and Xenopus Smad7 with bone morphogenetic protein receptors and transforming growth factor-β receptors. J Biol Chem 273: 25364–25370.
161. Suzuki C, Murakami G, Fukuchi M, Shimanuki T, Shikauchi Y, Imamura T, Miyazono K. 2002. Smurf1 regulates the inhibitory activity of Smad7 by targeting Smad7 to the plasma membrane. J Biol Chem 277: 39919–39925.
162. Tajima Y, Goto K, Yoshida M, Shinomiya K, Sekimoto T, Yoneda Y, Miyazono K, Imamura T. 2003. Chromosomal region maintenance 1 (CRM1)-dependent nuclear export of Smad ubiquitin regulatory factor 1 (Smurf1) is essential for negative regulation of transforming growth factor-β signaling by Smad7. J Biol Chem 278: 10716–10721.
163. Tan HL, Glen E, Töpf A, Hall D, O’Sullivan JJ, Sneddon L, Wren C, Avery P, Lewis RJ, ten Dijke P, et al. 2012. Nonsynonymous variants in the SMAD6 gene predispose to congenital cardiovascular malformation. Hum Mutat 33: 720–727.
164. Terada Y, Hanada S, Nakao A, Kuwahara M, Sasaki S, Marumo F. 2002. Gene transfer of Smad7 using electroporation of adenovirus prevents renal fibrosis in post-obstructed kidney. Kidney Int 61: 94–98.
165. Thisse C, Thisse B. 1999. Antivin, a novel and divergent member of the TGFb superfamily, negatively regulates mesoderm induction. Development 126: 229–240.
166. Tojo M, Takebe A, Takahashi S, Tanaka K, Imamura T, Miyazono K, Chiba T. 2012. Smad7-deficient mice show growth retardation with reduced viability. J Biochem 151: 621–631.
167. Topper JN, Cai J, Qiu Y, Anderson KR, Xu YY, Deeds JD, Feeley R, Gimeno CJ, Woolf EA, Tayber O, et al. 1997. Vascular MADs: Two novel MAD-related genes selectively inducible by flow in humanvascular endothelium. Proc Natl Acad Sci 94: 9314–9319.
168. Tsubakihara Y, Hikita A, Yamamoto S, Matsushita S, Matsushita N, Oshima Y, Miyazawa K, Imamura T. 2015. Arkadia enhances BMP signaling through ubiquitylation and degradation of Smad6. J Biochem 158: 61–71.
169. Tsuneizumi K, Nakayama T, Kamoshida Y, Kornberg TB, Christian JL, Tabata T. 1997. Daughters against dpp modulates dpp organizing activity in Drosophila wing development. Nature 389: 627–631.
170. Ulloa L, Doody J, Massagué J. 1999. Inhibition of transforming growth factor-β/SMAD signalling by the interferong-γ/STAT pathway. Nature 397: 710–713.
171. Valcourt U, Gouttenoire J, Moustakas A, Herbage D, Mallein-Gerin F. 2002. Functions of transforming growth factor-β family type I receptors and Smad proteins in the hypertrophic maturation and osteoblastic differentiation of chondrocytes. J Biol Chem 277: 33545–33558.
172. Valdimarsdottir G, Goumans MJ, Itoh F, Itoh S, Heldin CH, ten Dijke P. 2006. Smad7 and protein phosphatase 1a are critical determinants in the duration of TGF-β/ALK1 signaling in endothelial cells. BMC Cell Biol 7: 16.
173. Vale W, Rivier C, Hsueh A, Campen C, Meunier H, Bicsak T, Vaughan J, Corrigan A, Bardin W, Sawchenko P, et al. 1988. Chemical and biological characterization of the inhibin family of protein hormones. Recent Prog Horm Res 44: 1–34.
174. Wachs FP, Winner B, Couillard-Despres S, Schiller T, Aigner R, Winkler J, Bogdahn U, Aigner L. 2006. Transforming growth factor-β1 is a negative modulator of adult neurogenesis. J Neuropathol Exp Neurol 65: 358–370.
175. Wan M, Cao X, Wu Y, Bai S, Wu L, Shi X, Wang N, Cao X. 2002. Jab1 antagonizes TGF-β signaling by inducing Smad4 degradation. EMBO Rep 3: 171–176.
176. Wang H, Song K, Sponseller TL, Danielpour D. 2005. Novel function of androgen receptor-associated protein 55/ Hic-5 as a negative regulator of Smad3 signaling. J Biol Chem 280: 5154–5162.
177. Wang H, Song K, Krebs TL, Yang J, Danielpour D. 2008. Smad7 is inactivated through a direct physical interaction with the LIM protein Hic-5/ARA55. Oncogene 27: 6791-6805.
178. Wang J, Zhao J, Chu ES, Mok MT, Go MY, Man K, Heuchel R, Lan HY, Chang Z, Sung JJ, et al. 2013. Inhibitory role of Smad7 in hepatocarcinogenesis in mice and in vitro. J Pathol 230: 441–452.
179. Wei LH, Huang XR, Zhang Y, Li YQ, Chen HY, Heuchel R, Yan BP, Yu CM, Lan HY. 2013. Deficiency of Smad7 enhances cardiac remodeling induced by angiotensin II infusion in a mouse model of hypertension. PLoS ONE 8: e70195.
180. Wohlfert EA, Gorelik L, Mittler R, Flavell RA, Clark RB. 2006. Cutting edge: Deficiency in the E3 ubiquitin ligase Cbl-b results in a multifunctional defect in T cell TGF-β sensitivity in vitro and in vivo. J Immunol 176: 1316-1320.
181. Xavier S, Piek E, Fujii M, Javelaud D, Mauviel A, Flanders KC, Samuni AM, Felici A, Reiss M, Yarkoni S, et al. 2004. Amelioration of radiation-induced fibrosis: Inhibition of transforming growth factor-β signaling by halofuginone. J Biol Chem 279: 15167–15176.
182. Xia H, Ooi LL, Hui KM. 2013. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology 58: 629–641.
183. Xiao X, Gaffar I, Guo P, Wiersch J, Fischbach S, Peirish L, Song Z, El-Gohary Y, Prasadan K, Shiota C, et al. 2014. M2 macrophages promote β-cell proliferation by up-regulation of SMAD7. Proc Natl Acad Sci 111: 1211–1220.
184. Xie Z, Chen Y, Li Z, Bai G, Zhu Y, Yan R, Tan F, Chen YG, Guillemot F, Li L, et al. 2011. Smad6 promotes neuronal differentiation in the intermediate zone of the dorsal neural tube by inhibition of the Wnt/b-catenin pathway. Proc Natl Acad Sci 108: 12119–12124.
185. Xu J, Wang AH, Oses-Prieto J, Makhijani K, Katsuno Y, Pei M, Yan L, Zheng YG, Burlingame A, Brückner K, et al. 2013. Arginine methylation initiates BMP-induced Smad signaling. Mol Cell 51: 5–19.
186. Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N, Taniguchi T, Nishida E, Matsumoto K. 1995. Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction. Science 270: 2008–2011.
187. Yamamura Y, Hua X, Bergelson S, Lodish HF. 2000. Critical role of Smads and AP-1 complex in transforming growth factor-β-dependent apoptosis. J Biol Chem 275: 36295–36302.
188. Yamashita M, Fatyol K, Jin C, Wang X, Liu Z, Zhang YE. 2008. TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-β. Mol Cell 31: 918–924.
189. Yan X, Lin Z, Chen F, Zhao X, Chen H, Ning Y, Chen YG. 2009. Human BAMBI cooperates with Smad7 to inhibit transforming growth factor-β signaling. J Biol Chem 284: 30097–30104.
190. Yan X, Zhang J, Pan L, Wang P, Xue H, Zhang L, Gao X, Zhao X, Ning Y, Chen YG. 2011. TSC-22 promotes transforming growth factor b-mediated cardiac myofibroblast dif-ferentiation by antagonizing Smad7 activity. Mol Cell Biol 31: 3700–3709.
191. Yan XH, Pan J, Xiong WW, Cheng MZ, Sun YY, Zhang SP, Chen YG. 2014. Yin Yang 1 (YY1) synergizes with Smad7 to inhibit TGF-β signaling in the nucleus. Sci China Life Sci 57: 128–136.
192. Yan X, Liao H, Cheng M, Shi X, Lin X, Feng XH, Chen YG. 2016. Smad7 protein interacts with receptor-regulated Smads (R-Smads) to inhibit transforming growth factor-b (TGF-β)/Smad signaling. J Biol Chem 291: 382–392.
193. Yoshida Y, Tanaka S, Umemori H, Minowa O, Usui M, Ikematsu N, Hosoda E, Imamura T, Kuno J, Yamashita T, et al. 2000. Negative regulation of BMP/Smad signaling by Tob in osteoblasts. Cell 103: 1085–1097.
194. Yoshida Y, von Bubnoff A, Ikematsu N, Blitz IL, Tsuzuku JK, Yoshida EH, Umemori H, Miyazono K, Yamamoto T, Cho KW. 2003. Tob proteins enhance inhibitory Smadreceptor interactions to repress BMP signaling. Mech Dev 120: 629–637.
195. Zhang YE. 2009. Non-Smad pathways in TGF-β signaling. Cell Res 19: 128–139.
196. Zhang Y, Chang C, Gehling DJ, Hemmati-Brivanlou A, Derynck R. 2001. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc Natl Acad Sci 98: 97497–97499.
197. Zhang S, Fei T, Zhang L, Zhang R, Chen F, Ning Y, Han Y, Feng XH, Meng A, Chen YG. 2007. Smad7 antagonizes transforming growth factor b signaling in the nucleus by interfering with functional Smad-DNA complex formation. Mol Cell Biol 27: 4488–4499.
198. Zhang L, Huang H, Zhou F, Schimmel J, Pardo CG, Zhang T, Barakat TS, Sheppard KA, Mickanin C, Porter JA, et al. 2012. RNF12 controls embryonic stem cell fate and morphogenesis in zebrafish embryos by targeting Smad7 for degradation. Mol Cell 46: 650–661.
199. Zhang R, Huang H, Cao P, Wang Z, Chen Y, Pan Y. 2013a. Sma-and Mad-related protein 7 (Smad7) is required for embryonic eye development in the mouse. J Biol Chem 288: 10275–10285.
200. Zhang X, Zhang J, Bauer A, Zhang L, Selinger DW, Lu CX, ten Dijke P. 2013b. Fine-tuning BMP7 signalling in adipogenesis by UBE2O/E2–230K-mediated monoubiquitination of SMAD6. EMBO J 32: 996–1007.
201. Zhou F, Drabsch Y, Dekker TJ, de Vinuesa AG, Li Y, Hawinkels LJ, Sheppard KA, Goumans MJ, Luwor RB, de Vries CJ, et al. 2014. Nuclear receptor NR4A1 promotes breast cancer invasion and metastasis by activating TGF-β signalling. Nat Commun 5: 3388.
202. Zhu H, Kavsak P, Abdollah S, Wrana JL, Thomsen GH. 1999. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature 400: 687–693.
203. Zhu L, Wang L, Wang X, Luo X, Yang L, Zhang R, Yin H, Xie D, Pan Y, Chen Y. 2011. Hepatic deletion of Smad7 in mouse leads to spontaneous liver dysfunction and aggravates alcoholic liver injury. PLoS ONE 6: e17415.
204. Zhu L, Wang L, Luo X, Zhang Y, Ding Q, Jiang X, Wang X, Pan Y, Chen Y. 2012. Tollip, an intracellular trafficking protein, is a novel modulator of the transforming growth factor-β signaling pathway. J Biol Chem 287: 39653–39663.